DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker.

MLA

Zhang, Jingwen, et al. “DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker.” Frontiers in Oncology, vol. 11, June 2021, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fonc.2021.665360.

APA

Zhang, J., Fu, M., Zhang, M., Zhang, J., Du, Z., Zhang, H., Hua, W., & Mao, Y. (2021). DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker. Frontiers in Oncology, 11, 1–11. https://doi.org/10.3389/fonc.2021.665360

Chicago

Zhang, Jingwen, Minjie Fu, Mengli Zhang, Jinsen Zhang, Zunguo Du, Hongyi Zhang, Wei Hua, and Ying Mao. 2021. “DDX60 Is Associated With Glioma Malignancy and Serves as a Potential Immunotherapy Biomarker.” Frontiers in Oncology 11 (June): 1–11. doi:10.3389/fonc.2021.665360.